Bristol-Myers Squibb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of ZymoGenetics

by Benzinga Staff
September 28, 2010 7:38 AM | 22 seconds read |
Bristol-Myers Squibb Company BMY announced today that the Hart-Scott-Rodino (HSR) waiting period for its tender offer for ZymoGenetics, Inc. ZGEN has expired. Bristol-Myers Squibb initiated on September 10, 2010, through its wholly-owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all outstanding shares of common stock of ZymoGenetics for $9.75 per share. Analyze Any Stock FREE! Click Here.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsM&A
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!